Drug
Tiotropium
Tiotropium: highest development phase Post-Market, developed by Almirall, Boehringer Ingelheim. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall, Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tiotropium NCT02039050 | Post-Market | Pulmonary Disease, Chronic Obstructive |
| Tiotropium NCT00274534 | Phase 3 | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow Tiotropium on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.